Nanomedicine-Nanotechnology Biology and Medicine
·
2019
·
IF 5.57
Chao Teng,Zhuodong Chai,Zhongyue Yuan,Lianjie Ren,Chenshi Lin,Zhen Yan,Wei He,Chao Qin,Lei Yang,Xiaopeng Han,Lifang Yin
PEG coating was regarded as one effective method to improve the tumor-targeting efficiency of hyaluronic acid-based nanoparticles (HBN). However, the research of interaction between PEG coating and different receptors such as stabilin-2 and CD44 was limited. Herein, we synthesized a series of PEGylated hyaluronic acid with Curcumin (PHCs) to evaluate the role of PEG coating density in the interaction between HA and its receptors, which influenced tissues targeting activity, pharmacokinetic profiles and therapeutic efficacy of HBN. Compared with other counterparts, PHC HBN with about 5% PEG coating density preferably accumulated in the tumor mass, rather than in the liver, and hold desirable anti-cancer effect. These results indicated that to obtain optimized anticancer effect of HBN, the cellular uptake efficiency between different types of the cells should be carefully balanced by different PEG densities.
研究领域:
药剂学
·
肿瘤学
·
生物医学工程
✓ 已验证
产品关联
DOI
PubMed
高影响因子
DRUG METABOLISM AND DISPOSITION
·
2025
·
IF 4
Lanjing Li,Ru Huan,Ting Liang,Han Liu,Yao Dong,Shuang Chen,Chen Zhang,Chunshan Gui
Estradiol is the most potent and biologically active form of estrogen with glucuronide as its predominant conjugation form. Major estradiol glucuronides include estradiol-3-glucuronide (E 2 3G), estradiol-17β-glucuronide (E 2 17βG), and estradiol-3-sulfate-17β-glucuronide (E 2 3S17βG). Hepatic disposition of E 2 17βG involves basolateral uptake transporters organic anion transporting polypeptide (OATP) 1B1/1B3 and apical efflux transporters multidrug resistance-associated protein 2 (MRP2)/breast cancer resistance protein (BCRP). In addition, E 2 3G and E 2 3S17βG are substrates for MRP2/BCRP. However, whether E 2 3G and E 2 3S17βG across the basolateral membrane of hepatocytes are transporter-mediated and which transporters play the most significant roles are largely unknown. Therefore, in the present study we investigated the human hepatic uptake transporters for E 2 3G and E 2 3S17βG. Our results showed that E 2 3G and E 2 3S17βG are transported by human OATPs. Specifically, E 2 3G is a substrate for OATP1B1, 1B3, and 2B1, with K m values being of 16.0, 23.8, and 6.4 μM, respectively, and OATP2B1 possesses the highest transport efficiency. E 2 3S17βG is a substrate for OATP1B1 and 1B3, with K m values being of 0.5 and 23.7 μM, respectively, and OATP1B1 has a higher transport efficiency. At low concentrations, E 2 3G and E 2 3S17βG are selective substrates for OATP2B1 and OATP1B1, respectively. Furthermore, mutual and differential inhibition between E 2 3G/E 2 3S17βG and known OATP substrates/inhibitors has been observed. In summary, our results demonstrated that basolateral OATPs and apical MRP2/BCRP could constitute the hepatic vectorial transport of E 2 3G and E 2 3S17βG from the blood to the bile. Significance Statement This study demonstrated that OATP1B1/1B3/2B1 are hepatic uptake transporters for E 2 3G, and OATP1B1/1B3 are hepatic uptake transporters for E 2 3S17βG. At low concentrations, E 2 3G and E 2 3S17βG are selectively transported by OATP2B1 and OATP1B1, respectively. The findings in this study unveil the underlying molecular mechanisms for the hepatic disposition of estradiol glucuronides E 2 3G and E 2 3S17βG.
研究领域:
药理学
·
生物化学
·
分子生物学
·
生理学
·
药物代谢
✓ 已验证
产品关联
DOI
PubMed
高影响因子
PHARMACEUTICAL BIOLOGY
·
2022
·
IF 3.889
Ruifeng Liang,Wenjing Ge,Bingjie Li,Weifeng Cui,Xiaofan Ma,Yuying Pan,Gengsheng Li
Context Patients with non-alcoholic steatohepatitis (NASH) may have a simultaneous intake of pravastatin and evodiamine-containing herbs.Objective The effect of evodiamine on the pharmacokinetics of pravastatin and its potential mechanisms were investigated in NASH rats.Materials and methods The NASH model was conducted with feeding a methionine choline-deficient (MCD) diet for 8 weeks. Sprague-Dawley rats were randomised equally (n = 6) into NASH group, evodiamine group (10 mg/kg), pravastatin group (10 mg/kg), and evodiamine (10 mg/kg) + pravastatin (10 mg/kg) group. Normal control rats were fed a standard diet. Effects of evodiamine on the pharmacokinetics, distribution, and uptake of pravastatin were investigated.Results Evodiamine decreased Cmax (159.43 ± 26.63 vs. 125.61 ± 22.17 μg/L), AUC0-t (18.17 ± 2.52 vs. 14.91 ± 2.03 mg/min/L) and AUC0-∞ (22.99 ± 2.62 vs. 19.50 ± 2.31 mg/min/L) of orally administered pravastatin in NASH rats, but had no significant effect in normal rats. Evodiamine enhanced the uptake (from 154.85 ± 23.17 to 198.48 ± 26.31 pmol/mg protein) and distribution (from 736.61 ± 108.07 to 911.89 ± 124.64 ng/g tissue) of pravastatin in NASH rat liver. The expression of Oatp1a1, Oatp1a4, and Oatp1b2 was up-regulated 1.48-, 1.38-, and 1.51-fold by evodiamine. Evodiamine decreased the levels of IL-1β, IL-6, and TNF-α by 27.82%, 24.76%, and 29.72% in NASH rats, respectively.Discussion and conclusions Evodiamine decreased the systemic exposure of pravastatin by up-regulating the expression of OATPs. These results provide a reference for further validation of this interaction in humans.
研究领域:
药理学
·
肝病学
·
药代动力学
·
炎症
✓ 已验证
产品关联
DOI
PubMed
高影响因子
ORGANIC & BIOMOLECULAR CHEMISTRY
·
2020
·Vol. 18
·期 18
·3512-3521
·
IF 3.412
Shijie Wang,Dingyao Gao,Ke Li,Siqin Ye,Qingzhu Liu,Ying Peng,Gaochao Lv,Ling Qiu,Jianguo Lin
Early evaluation of the therapy efficiency can promote the development of anti-tumor drugs and optimization of the treatment method. Caspase-3 is a key biomarker for early apoptosis. Detection of caspase-3 activity is essential for quick assessment of the curative effect. We have reported a PET probe that could image drug-induced tumor apoptosis in vivo. However, high liver uptake limits its application. In order to optimize the pharmacokinetics of the previous probe, we introduced a hydrophilic peptide sequence to minimize liver uptake. The structure of the new probe was confirmed by mass spectrometry and nuclear magnetic resonance. This probe was able to cross the cell membrane freely and could be converted into a dimer through the condensation reaction of 2-cyano-6-aminobenzothiazole (CBT) and cysteine in response to intracellular activated caspase-3 and glutathione (GSH). The hydrophobic dimers further self-assembled into nanoparticles, which could enhance the probe aggregation in apoptotic tumor tissues. In vivo experiments showed that the tumor uptake of the new probe was higher than that of the previous probe, while the liver uptake of the new probe was significantly reduced. The new probe might be promising in imaging apoptotic tumors with suitable pharmacokinetics.
研究领域:
放射药理学
·
医学影像
·
肿瘤学
·
药物动力学
✓ 已验证
DOI
PubMed
高影响因子
ANALYTICAL CHEMISTRY
·
2020
·
IF 6.785
Ling Qiu,Xi Li,Gaochao Lv,Yann Seimbille,Ke Li,Ying Peng,Qingzhu Liu,Minhao Xie,Jianguo Lin
Overexpression of legumain is closely associated with tumor proliferation, invasion, and metastasis. Because of its intrinsic properties, such as high sensitivity and resolution, positron emission tomography (PET) has become an effective imaging technique for early diagnosis, treatment response prediction, and monitoring. Herein, two legumain-targeting radiofluorinated smart probes (18F-2 and 18F-3) as well as a control probe (18F-1) were specifically designed for PET imaging of legumain activity in tumors. 18F-1, 18F-2, and 18F-3 were obtained with high radiochemical yield (RCY > 60%) and radiochemical purity (RCP > 99%) using a convenient “one-step” 18F-labeling method. The probes 18F-2 and 18F-3 exhibited high response to legumain activity and reductive environment and revealed comparable uptake in HCT116 cells (4.22% ± 0.14% and 4.64% ± 0.32% for 18F-2 and 18F-3, respectively; 8.46% ± 0.33% and 9.05% ± 0.24% for co-treatment of 18F-2 + 2 and 18F-3 + 3 at 1 h), while the control probe 18F-1 showed no response. PET imaging of tumor-bearing mice showed that the co-injection strategy (18F-2 + 2 and 18F-3 + 3) resulted in higher tumor uptake (3.57% ± 0.37% and 3.72% ± 0.19% ID/g at 10 min, respectively) than the single injection strategy (2.59% ± 0.19% and 2.60% ± 0.46% ID/g for 18F-2 and 18F-3, respectively). In addition, introduction of the trimeric histidine-glutamate (HEHEHE) tag to 18F-3 reduced the liver uptake by almost two-fold without any noticeable effect on the tumor uptake. All the results indicate that 18F-3 holds great potential applications in clinics for sensitive and specific PET imaging of legumain activity in tumors.
研究领域:
医学成像
·
癌症研究
·
分子生物学
·
放射学
✓ 已验证
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）